Quintiles Draws Curtain On Phase I India Unit As External Business Environment Gets Challenging
This article was originally published in The Pink Sheet Daily
The leading CRO shutters its Phase I unit in Hyderabad inaugurated only two years ago. The decision signifies the tough regulatory challenges global companies are facing in India.
You may also be interested in...
MUMBAI - Quintiles Transnational Corp.'s India CEO Ferzaan Engineer will step down after serving the multinational contract research organization since its inception in India more than 13 years ago
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.